[go: up one dir, main page]

WO2014024026A8 - Method for eliciting in infants an immune response against rsv and b. pertussis - Google Patents

Method for eliciting in infants an immune response against rsv and b. pertussis Download PDF

Info

Publication number
WO2014024026A8
WO2014024026A8 PCT/IB2013/001722 IB2013001722W WO2014024026A8 WO 2014024026 A8 WO2014024026 A8 WO 2014024026A8 IB 2013001722 W IB2013001722 W IB 2013001722W WO 2014024026 A8 WO2014024026 A8 WO 2014024026A8
Authority
WO
WIPO (PCT)
Prior art keywords
pertussis
infants
rsv
eliciting
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/001722
Other languages
French (fr)
Other versions
WO2014024026A1 (en
Inventor
Ann-Muriel Steff
Stephane T. TEMMERMAN
Jean-François TOUSSAINT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP18215004.5A priority Critical patent/EP3488865A1/en
Priority to JP2015525952A priority patent/JP2015525794A/en
Priority to CA2879939A priority patent/CA2879939A1/en
Priority to SG11201500573RA priority patent/SG11201500573RA/en
Priority to BR112015002549A priority patent/BR112015002549A2/en
Priority to CN201380052284.2A priority patent/CN104755100B/en
Priority to EP13774498.3A priority patent/EP2879704A1/en
Priority to AU2013301312A priority patent/AU2013301312A1/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to US14/419,990 priority patent/US20150202283A1/en
Publication of WO2014024026A1 publication Critical patent/WO2014024026A1/en
Priority to ZA2015/00676A priority patent/ZA201500676B/en
Anticipated expiration legal-status Critical
Publication of WO2014024026A8 publication Critical patent/WO2014024026A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) and Bordetella pertussis through maternal immunization using recombinant respiratory syncytial virus (RSV) and B. pertussis antigens to reduce the incidence or severity of RSV and pertussis infection in young infants.
PCT/IB2013/001722 2012-08-06 2013-08-05 Method for eliciting in infants an immune response against rsv and b. pertussis Ceased WO2014024026A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP13774498.3A EP2879704A1 (en) 2012-08-06 2013-08-05 Method for eliciting in infants an immune response against rsv and b. pertussis
CA2879939A CA2879939A1 (en) 2012-08-06 2013-08-05 Novel method
SG11201500573RA SG11201500573RA (en) 2012-08-06 2013-08-05 Method for eliciting in infants an immune response against rsv and b. pertussis
BR112015002549A BR112015002549A2 (en) 2012-08-06 2013-08-05 vaccination regimen to protect a child against respiratory syncytial virus infection or disease, immunogenic composition or plurality of immunogenic compositions, use of an immunogenic composition or a plurality of immunogenic compositions
CN201380052284.2A CN104755100B (en) 2012-08-06 2013-08-05 Method for causing the immunne response for RSV and Bordetella pertussis in baby
EP18215004.5A EP3488865A1 (en) 2012-08-06 2013-08-05 Method for eliciting in infants an immune response against rsv and b. pertussis
JP2015525952A JP2015525794A (en) 2012-08-06 2013-08-05 Method for eliciting an immune response against RSV and Bordetella pertussis in infants
AU2013301312A AU2013301312A1 (en) 2012-08-06 2013-08-05 Method for eliciting in infants an immune response against RSV and B. pertussis
US14/419,990 US20150202283A1 (en) 2012-08-06 2013-08-05 Method for eliciting in infants an immune response against rsv and b. pertussis
ZA2015/00676A ZA201500676B (en) 2012-08-06 2015-01-29 Method for eliciting in infants an immune response against rsv and b. pertussis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261679928P 2012-08-06 2012-08-06
US61/679,928 2012-08-06
US201313138358A 2013-03-15 2013-03-15
US13/,835,829 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014024026A1 WO2014024026A1 (en) 2014-02-13
WO2014024026A8 true WO2014024026A8 (en) 2015-04-02

Family

ID=50067471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/001722 Ceased WO2014024026A1 (en) 2012-08-06 2013-08-05 Method for eliciting in infants an immune response against rsv and b. pertussis

Country Status (5)

Country Link
JP (1) JP2015525794A (en)
AU (1) AU2013301312A1 (en)
CA (1) CA2879939A1 (en)
SG (1) SG11201500573RA (en)
WO (1) WO2014024026A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
CN105555304A (en) * 2013-08-05 2016-05-04 葛兰素史密丝克莱恩生物有限公司 Combination immunogenic compositions
AU2018353409B2 (en) * 2017-10-18 2025-07-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) Bordetella strains expressing serotype 3 Fimbriae
EP3890770A4 (en) * 2018-12-05 2022-09-28 Sanofi Pasteur, Inc. Pertussis booster vaccine
CN114025793A (en) * 2019-02-28 2022-02-08 诺瓦瓦克斯股份有限公司 Methods for preventing diseases or disorders caused by RSV infection

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
ATE80179T1 (en) 1986-12-23 1992-09-15 Univ Leland Stanford Junior MODIFIED PERTUSSI TOXIN.
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
JP2918895B2 (en) 1987-09-04 1999-07-12 アムジエン・インコーポレーテツド Bordetella toxin subunit analogs derived from recombinant DNA
IT1223334B (en) 1987-11-02 1990-09-19 Sclavo Spa IMMUNOLOGICALLY ACTIVE POLYPEPTIDES WITH AN ALTERED TOXICITY USEFUL FOR THE PREPARATION OF AN ANTIPERTOX VACCINE
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
DE69022106T2 (en) 1989-04-28 1996-02-15 Sclavo Spa Pertussis toxin mutants, the same producing Bordetella strains and their use as a vaccine against pertussis.
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ATE129159T1 (en) 1990-02-12 1995-11-15 Smithkline Beecham Biolog VACCINE.
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
ATE444079T1 (en) 1992-05-23 2009-10-15 Glaxosmithkline Biolog Sa COMBINED VACCINES CONTAINING HEPATITIS B SURFACE ANTIGEN AND OTHER ANTIGENS
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
CN1087176C (en) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 Vaccine preparations containing 3-O deacylated monophosphoryl lipid A
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
PL181241B1 (en) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Glucosoamine disaccharides, method of obtaining them and pharmaceutical composition containing them as well as their application
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
DK0772619T4 (en) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
DE69612198T3 (en) 1995-06-23 2011-08-18 Smithkline Beecham Biologicals S.A. A vaccine composition consisting of a Haemophilus influenzae B polysaccharide antigen conjugate adsorbed to aluminum phosphate
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
SK18602000A3 (en) 1998-06-08 2001-07-10 Sca Emballage France Fast flattening packaging
HUP0102475A3 (en) 1998-06-30 2001-12-28 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6379324B1 (en) 1999-06-09 2002-04-30 The Procter & Gamble Company Intracutaneous microneedle array apparatus
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
ES2375704T5 (en) 2000-06-29 2016-03-03 Smithkline Beecham Biologicals S.A. Composition of multivalent vaccine
ATE489968T1 (en) 2001-03-09 2010-12-15 Id Biomedical Corp Quebec PROTEOSOME-LIPOSACCHARIDE VACCINE ADJUVANT
ATE404561T1 (en) 2001-04-17 2008-08-15 Dainippon Sumitomo Pharma Co NEW ADENINE DERIVATIVES
US20040087992A1 (en) 2002-08-09 2004-05-06 Vladimir Gartstein Microstructures for delivering a composition cutaneously to skin using rotatable structures
ES2318615T3 (en) 2001-11-16 2009-05-01 Coley Pharmaceutical Group, Inc. N- (4- (4-AMINO-2-ETIL-1H-IMIDAZO (4,5-C) QUINOLIN-1-IL) BUTIL) METHANOSULPHONAMIDE, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES ITSELF.
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
ES2346314T3 (en) 2003-10-02 2010-10-14 Glaxosmithkline Biolog Sa ANTIGENS OF B. PERTUSSIS AND USE OF THE SAME IN VACCINATION.
BRPI0402630B8 (en) 2004-07-05 2021-05-25 Fund Butantan process of obtaining a less reactogenic cellular pertussis vaccine
CA2588080C (en) 2004-11-18 2013-01-08 3M Innovative Properties Company Masking method for coating a microneedle array
AU2005306372B2 (en) 2004-11-18 2011-01-06 Kindeva Drug Delivery L.P. Method of contact coating a microneedle array
PT1828378E (en) 2004-12-17 2014-10-10 Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Sport Deacylation of lps in gram negative bacteria
JP2010522540A (en) * 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック Chimeric antigen
US9114238B2 (en) 2007-04-16 2015-08-25 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
WO2009048607A1 (en) 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
ES2634667T3 (en) 2009-04-24 2017-09-28 Corium International, Inc. Methods for manufacturing microprojection assemblies
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
PT2445526T (en) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Recombinant rsv antigens
EP2453918B1 (en) 2009-07-15 2015-12-16 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
LT2667892T (en) * 2011-01-26 2019-05-10 Glaxosmithkline Biologicals Sa Rsv immunization regimen

Also Published As

Publication number Publication date
WO2014024026A1 (en) 2014-02-13
AU2013301312A1 (en) 2015-03-19
CA2879939A1 (en) 2014-02-13
SG11201500573RA (en) 2015-02-27
JP2015525794A (en) 2015-09-07

Similar Documents

Publication Publication Date Title
HK1254950A1 (en) Antibody neutralizing human respiratory syncytial virus
WO2014024026A8 (en) Method for eliciting in infants an immune response against rsv and b. pertussis
WO2009039229A3 (en) Method of conferring a protective immune response to norovirus
WO2010135749A9 (en) Herpes simplex virus type2: compositions and methods for eliciting an immune response
WO2015142671A3 (en) Influenza virus vectors and uses therefor
WO2014160463A8 (en) Prefusion rsv f proteins and their use
WO2014009438A3 (en) Mycobacterial antigen vaccine
WO2013054199A3 (en) Cmv antigens and uses thereof
CR20120025A (en) RECOMBINANT RESPIRATORY SYMPTOM VIRUS ANTIGENS
TR201908715T4 (en) Rsv immunization regimen.
PH12015500956B1 (en) Novel mucosal adjuvants and delivery systems
CA2763359C (en) New human rotavirus strains and vaccines
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2016001695A (en) Combination immunogenic compositions.
ZA201500676B (en) Method for eliciting in infants an immune response against rsv and b. pertussis
EP2753354A4 (en) SUBUNIT VACCINE AGAINST NANOEMULSION SYNCYTIAL RESPIRATORY VIRUS (RSV)
WO2011080271A3 (en) Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof
WO2012047267A3 (en) Polyvalent immunogen
MX2025005156A (en) Respiratory syncytial virus rna vaccination
HK1210475A1 (en) Herpes simplex virus vaccine
WO2012074881A3 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2013173256A3 (en) New and improved influenza vaccines
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
WO2013014408A3 (en) Vaccine
WO2010080188A3 (en) Epitope targeted anthrax vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13774498

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2879939

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015525952

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14419990

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2013774498

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013301312

Country of ref document: AU

Date of ref document: 20130805

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015002549

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015002549

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150205

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112015002549

Country of ref document: BR

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112015002549

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150205

ENPC Correction to former announcement of entry into national phase, pct application did not enter into the national phase

Ref country code: BR

Free format text: ANULADA A PUBLICACAO CODIGO 1.3 NA RPI NO 2426 DE 04/07/2017 POR TER SIDO INDEVIDA.